Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 65
Filter
1.
Clin Exp Rheumatol ; 32(5): 689-96, 2014.
Article in English | MEDLINE | ID: mdl-25068290

ABSTRACT

OBJECTIVES: We aimed to assess changes in myositis core set measures and ancillary clinical and laboratory data from the National Institutes of Health's subset of patients enrolled in the Rituximab in Myositis trial. METHODS: Eighteen patients (5 dermatomyositis, 8 polymyositis, 5 juvenile dermatomyositis) completed more in-depth testing of muscle strength and cutaneous assessments, patient-reported outcomes, and laboratory tests before and after administration of rituximab. Percentage change in individual measures and in the definitions of improvement (DOIs) and standardized response means were examined over 44 weeks. RESULTS: Core set activity measures improved by 18-70% from weeks 0-44 and were sensitive to change. Fifteen patients met the DOI at week 44, 9 patients met a DOI 50% response, and 4 met a DOI 70% response. Muscle strength and function measures were more sensitive to change than cutaneous assessments. Constitutional, gastrointestinal, and pulmonary systems improved 44-70%. Patient-reported outcomes improved up to 28%. CD20+ B cells were depleted in the periphery, but B cell depletion was not associated with clinical improvement at week 16. CONCLUSIONS: This subset of patients had high rates of clinical response to rituximab, similar to patients in the overall trial. Most measures were responsive, and muscle strength had a greater degree of change than cutaneous assessments. Several novel assessment tools, including measures of strength and function, extra-muscular organ activity, fatigue, and health-related quality of life, are promising for use in future myositis trials. Further study of B cell-depleting therapies in myositis, particularly in treatment-naïve patients, is warranted.


Subject(s)
Anti-Inflammatory Agents/therapeutic use , Antibodies, Monoclonal, Murine-Derived/therapeutic use , Myositis/drug therapy , Adolescent , Adult , B-Lymphocytes/drug effects , B-Lymphocytes/immunology , Biomarkers/blood , Child , Female , Health Status Indicators , Humans , Male , Middle Aged , Muscle Strength/drug effects , Myositis/blood , Myositis/diagnosis , Myositis/physiopathology , Predictive Value of Tests , Recovery of Function , Remission Induction , Rituximab , Skin/drug effects , Skin/pathology , Surveys and Questionnaires , Time Factors , Treatment Outcome
2.
Genome Res ; 22(5): 850-9, 2012 May.
Article in English | MEDLINE | ID: mdl-22310478

ABSTRACT

Atopic dermatitis (AD) has long been associated with Staphylococcus aureus skin colonization or infection and is typically managed with regimens that include antimicrobial therapies. However, the role of microbial communities in the pathogenesis of AD is incompletely characterized. To assess the relationship between skin microbiota and disease progression, 16S ribosomal RNA bacterial gene sequencing was performed on DNA obtained directly from serial skin sampling of children with AD. The composition of bacterial communities was analyzed during AD disease states to identify characteristics associated with AD flares and improvement post-treatment. We found that microbial community structures at sites of disease predilection were dramatically different in AD patients compared with controls. Microbial diversity during AD flares was dependent on the presence or absence of recent AD treatments, with even intermittent treatment linked to greater bacterial diversity than no recent treatment. Treatment-associated changes in skin bacterial diversity suggest that AD treatments diversify skin bacteria preceding improvements in disease activity. In AD, the proportion of Staphylococcus sequences, particularly S. aureus, was greater during disease flares than at baseline or post-treatment, and correlated with worsened disease severity. Representation of the skin commensal S. epidermidis also significantly increased during flares. Increases in Streptococcus, Propionibacterium, and Corynebacterium species were observed following therapy. These findings reveal linkages between microbial communities and inflammatory diseases such as AD, and demonstrate that as compared with culture-based studies, higher resolution examination of microbiota associated with human disease provides novel insights into global shifts of bacteria relevant to disease progression and treatment.


Subject(s)
Dermatitis, Atopic/microbiology , Metagenome , Skin/microbiology , Adolescent , Case-Control Studies , Child , Child, Preschool , Databases, Genetic , Dermatitis, Atopic/pathology , Humans , Molecular Typing , RNA, Bacterial/genetics , RNA, Ribosomal, 16S/genetics , Sequence Analysis, RNA , Staphylococcal Infections/microbiology , Staphylococcal Infections/pathology , Staphylococcus/genetics , Statistics, Nonparametric
3.
Arthritis Rheum ; 64(6): 2022-7, 2012 Jun.
Article in English | MEDLINE | ID: mdl-22161697

ABSTRACT

OBJECTIVE: To describe the genotypes, phenotypes, immunophenotypes, and treatments of PAPA syndrome (pyogenic sterile arthritis, pyoderma gangrenosum, and acne), a rare autoinflammatory disease, in 5 patients. METHODS: Clinical information was gathered from medical records and through interviews with 5 patients from 4 kindreds. PSTPIP1 (CD2BP1) exon 10 and exon 11 sequencing was performed in each patient. Neutrophil granule content and cytokine levels were determined in plasma and stimulated peripheral blood mononuclear cells (PBMCs) from patients and controls. RESULTS: We identified 2 previously described PAPA syndrome-associated PSTPIP1 mutations, A230T and E250Q, and a novel change, E250K. Disease penetrance was incomplete, with variable expressivity. The cutaneous manifestations included pathergy, cystic acne, and pyoderma gangrenosum. Interleukin-1ß (IL-1ß) and circulating neutrophil granule enzyme levels were markedly elevated in patients compared to those in controls. PBMC stimulation studies demonstrated impaired production of IL-10 and enhanced production of granulocyte-macrophage colony-stimulating factor. Good resolution of pyoderma gangrenosum was achieved in 3 patients with tumor necrosis factor α (TNFα) blockade treatment. CONCLUSION: This analysis of 5 patients demonstrates that mutations in PSTPIP1 are incompletely penetrant and variably expressed in the PAPA syndrome. Neutrophil granule proteins are markedly elevated ex vivo and in the plasma, and elevated levels might be compatible with a diagnosis of PAPA syndrome. TNFα blockade appears to be effective in treating the cutaneous manifestations of PAPA syndrome.


Subject(s)
Acne Vulgaris/diagnosis , Adaptor Proteins, Signal Transducing/genetics , Antirheumatic Agents/therapeutic use , Arthritis, Infectious/diagnosis , Cytoskeletal Proteins/genetics , Interleukin 1 Receptor Antagonist Protein/therapeutic use , Pyoderma Gangrenosum/diagnosis , Acne Vulgaris/drug therapy , Acne Vulgaris/genetics , Adolescent , Arthritis, Infectious/drug therapy , Arthritis, Infectious/genetics , Child , Disease Progression , Female , Genotype , Humans , Infant, Newborn , Male , Middle Aged , Mutation , Phenotype , Pyoderma Gangrenosum/drug therapy , Pyoderma Gangrenosum/genetics , Syndrome , Treatment Outcome , Young Adult
4.
Arch Dermatol ; 148(1): 79-84, 2012 Jan.
Article in English | MEDLINE | ID: mdl-21931011

ABSTRACT

BACKGROUND: Mutations in the dedicator of cytokinesis 8 gene (DOCK8) cause a combined primary immunodeficiency syndrome that is characterized by elevated serum IgE levels, depressed IgM levels, eosinophilia, sinopulmonary infections, cutaneous viral infections, and lymphopenia. Many patients with DOCK8 deficiency were previously thought to have a variant of Job's syndrome. Distinguishing between DOCK8 deficiency and Job's syndrome, also referred to as autosomal dominant hyper-IgE syndrome, on the basis of clinical findings alone is challenging. The discovery of the DOCK8 mutation has made it possible to differentiate the cutaneous manifestations of these hyper-IgE syndromes. OBSERVATIONS: Twenty-one patients from 14 families with confirmed homozygous or compound heterozygous mutations in DOCK8 were evaluated. Clinical findings included dermatitis, asthma, food and environmental allergies, recurrent sinopulmonary infections, staphylococcal skin abscesses, and severe cutaneous viral infections. Malignant neoplasms, including aggressive cutaneous T-cell lymphoma, anal and vulvar squamous cell carcinomas, and diffuse large B-cell lymphoma, developed in 5 patients during adolescence and young adulthood. CONCLUSIONS: DOCK8 deficiency and Job's syndrome share several clinical features, including elevated serum IgE levels, dermatitis, recurrent sinopulmonary infections, and cutaneous staphylococcal abscesses. However, the presence of recalcitrant, widespread cutaneous viral infections, asthma, and food and environmental allergies, as well as the absence of newborn rash and coarse facies, favors the clinical diagnosis of DOCK8 deficiency. Rates of malignancy and overall mortality in patients with DOCK8 deficiency were higher than in those with Job's syndrome, highlighting the value of distinguishing between these conditions and the importance of close monitoring for neoplasia.


Subject(s)
Guanine Nucleotide Exchange Factors/deficiency , Guanine Nucleotide Exchange Factors/genetics , Job Syndrome/diagnosis , Mutation , Skin Diseases/diagnosis , Skin Diseases/genetics , Adolescent , Adult , Child , Child, Preschool , Diagnosis, Differential , Female , Humans , Infant , Male , Syndrome , Young Adult
6.
Biol Blood Marrow Transplant ; 17(11): 1619-29, 2011 Nov.
Article in English | MEDLINE | ID: mdl-21536143

ABSTRACT

The lack of standardized criteria for measuring therapeutic response is a major obstacle to the development of new therapeutic agents for chronic graft-versus-host disease (cGVHD). National Institutes of Health (NIH) consensus criteria for evaluating therapeutic response were published in 2006. We report the results of 4 consecutive pilot trials evaluating the feasibility and estimating the interrater reliability and minimum detectable change of these response criteria. Hematology-oncology clinicians with limited experience in applying the NIH cGVHD response criteria (n = 34) participated in a 2.5-hour training session on response evaluation in cGVHD. Feasibility and interrater reliability between subspecialty cGVHD experts and this panel of clinician raters were examined in a sample of 25 children and adults with cGVHD. The minimum detectable change was calculated using the standard error of measurement. Clinicians' impressions of the brief training session, the photo atlas, and the response criteria documentation tools were generally favorable. Performing and documenting the full set of response evaluations required a median of 21 minutes (range: 12-60 minutes) per rater. The Schirmer tear test required the greatest time of any single test (median: 9 minutes). Overall, interrater agreement for skin and oral manifestations was modest; however, in the third and fourth trials, the agreement between clinicians and experts for all dimensions except movable sclerosis approached satisfactory values. In the final 2 trials, the threshold for defining change exceeding measurement error was 19% to 22% body surface area (BSA) for erythema, 18% to 26% BSA for movable sclerosis, 17% to 21% BSA for nonmovable sclerosis, and 2.1 to 2.6 points on the 15-point NIH Oral cGHVD scale. Agreement between clinician-expert pairs was moderate to substantial for the measures of functional capacity and for the gastrointestinal and global cGVHD rating scales. These results suggest that the NIH response criteria are feasible for use, and these reliability estimates are encouraging, because they were observed following a single 2.5-hour training session given at multiple transplant centers, with no opportunity for iterative training and calibration. Research is needed to evaluate inter- and intrarater reliability in larger samples, and to evaluate these response criteria as predictors of outcomes in clinical trials.


Subject(s)
Graft vs Host Disease/diagnosis , Graft vs Host Disease/therapy , Adolescent , Adult , Aged , Child , Child, Preschool , Chronic Disease , Female , Hematology/education , Humans , Leukemia/surgery , Lymphoma/surgery , Male , Middle Aged , Multiple Myeloma/surgery , National Institutes of Health (U.S.) , Pilot Projects , Prospective Studies , Stem Cell Transplantation/adverse effects , United States , Young Adult
8.
Pediatrics ; 126(5): e1248-52, 2010 Nov.
Article in English | MEDLINE | ID: mdl-20956421

ABSTRACT

Hypomorphic mutations that lead to "leaky" severe combined immunodeficiency presentation with partial protein function are increasingly being identified. Mutations in recombination-activating genes (RAGs) 1 and 2 cause immunodeficiency and dysregulation ranging from severe combined immunodeficiency to Omenn syndrome to more mild immunodeficiencies. We report here the cases of 3 patients with hypomorphic RAG1 mutations with distinct presentations. One patient had granulomatous skin disease and disseminated nontuberculous mycobacteria; the second patient presented with predominantly autoimmune manifestations; and the third patient presented with relatively late onset of infections and had isolated T-cell lymphopenia. These disparate and atypical presentations of hypomorphic RAG1 mutations highlight the role of RAG1 in immune function and autoimmunity and expand the disease spectrum linked to these genes.


Subject(s)
Alleles , Autoimmune Diseases/genetics , DNA Mutational Analysis , Granulomatous Disease, Chronic/genetics , Homeodomain Proteins/genetics , Lymphopenia/genetics , Mycobacterium avium-intracellulare Infection/genetics , Opportunistic Infections/genetics , Phenotype , Severe Combined Immunodeficiency/genetics , T-Lymphocytes/immunology , Autoimmune Diseases/diagnosis , Autoimmune Diseases/immunology , CD4 Lymphocyte Count , Child, Preschool , Fatal Outcome , Female , Genetic Carrier Screening , Granulomatous Disease, Chronic/diagnosis , Humans , Infant , Lymphopenia/diagnosis , Lymphopenia/immunology , Male , Mycobacterium avium-intracellulare Infection/diagnosis , Mycobacterium avium-intracellulare Infection/immunology , Opportunistic Infections/diagnosis , Opportunistic Infections/immunology , Severe Combined Immunodeficiency/diagnosis , Severe Combined Immunodeficiency/immunology
9.
Arch Dermatol ; 146(5): 523-6, 2010 May.
Article in English | MEDLINE | ID: mdl-20479300

ABSTRACT

BACKGROUND: Pyoderma gangrenosum-like ulcers and cellulitis of the lower extremities associated with recurrent fevers in patients with X-linked (Bruton) agammaglobulinemia have been reported to be caused by Helicobacter bilis (formerly classified as Flexispira rappini and then Helicobacter strain flexispira taxon 8). Consistent themes in these reports are the difficulty in recovering this organism in blood and wound cultures and in maintaining isolates in vitro. We confirmed the presence of this organism in a patient's culture by using a novel application of gene amplification polymerase chain reaction and electrospray ionization time-of-flight mass spectrometry. OBSERVATION: An adolescent boy with X-linked agammaglobulinemia presented with indurated plaques and a chronic leg ulcer whose origin was strongly suspected to be an H bilis organism. Histologic analysis demonstrated positive Warthin-Starry staining of curvilinear rods, which grew in culture but failed to grow when subcultured. They could not be identified by conventional techniques. A combination of gene amplification by polymerase chain reaction and electrospray ionization time-of-flight mass spectrometry confirmed the identity of this organism. CONCLUSIONS: This novel technology was useful in the identification of a difficult-to-grow Helicobacter organism, the cause of pyoderma gangrenosum-like leg ulcers in patients with X-linked agammaglobulinemia. Correct identification of this organism as the cause of pyoderma gangrenosum-like ulcers in patients with X-linked agammaglobulinemia is of great importance for the early initiation of appropriate and curative antibiotic therapy.


Subject(s)
Agammaglobulinemia/complications , Helicobacter Infections/diagnosis , Helicobacter/isolation & purification , Pyoderma Gangrenosum/diagnosis , Adolescent , Genetic Diseases, X-Linked/complications , Helicobacter/genetics , Helicobacter Infections/etiology , Helicobacter Infections/microbiology , Humans , Male , Polymerase Chain Reaction/methods , Pyoderma Gangrenosum/etiology , Pyoderma Gangrenosum/microbiology , Spectrometry, Mass, Electrospray Ionization/methods
11.
Blood ; 115(8): 1519-29, 2010 Feb 25.
Article in English | MEDLINE | ID: mdl-20040766

ABSTRACT

We identified 18 patients with the distinct clinical phenotype of susceptibility to disseminated nontuberculous mycobacterial infections, viral infections, especially with human papillomaviruses, and fungal infections, primarily histoplasmosis, and molds. This syndrome typically had its onset in adulthood (age range, 7-60 years; mean, 31.1 years; median, 32 years) and was characterized by profound circulating monocytopenia (mean, 13.3 cells/microL; median, 14.5 cells/microL), B lymphocytopenia (mean, 9.4 cells/microL; median, 4 cells/microL), and NK lymphocytopenia (mean, 16 cells/microL; median, 5.5 cells/microL). T lymphocytes were variably affected. Despite these peripheral cytopenias, all patients had macrophages and plasma cells at sites of inflammation and normal immunoglobulin levels. Ten of these patients developed 1 or more of the following malignancies: 9 myelodysplasia/leukemia, 1 vulvar carcinoma and metastatic melanoma, 1 cervical carcinoma, 1 Bowen disease of the vulva, and 1 multiple Epstein-Barr virus(+) leiomyosarcoma. Five patients developed pulmonary alveolar proteinosis without mutations in the granulocyte-macrophage colony-stimulating factor receptor or anti-granulocyte-macrophage colony-stimulating factor autoantibodies. Among these 18 patients, 5 families had 2 generations affected, suggesting autosomal dominant transmission as well as sporadic cases. This novel clinical syndrome links susceptibility to mycobacterial, viral, and fungal infections with malignancy and can be transmitted in an autosomal dominant pattern.


Subject(s)
Genetic Diseases, Inborn/genetics , Genetic Predisposition to Disease/genetics , Leukopenia/genetics , Mycobacterium Infections/genetics , Mycoses/genetics , Myelodysplastic Syndromes/genetics , Papillomavirus Infections/genetics , Pedigree , Adolescent , Adult , Child , Female , Fungi , Genetic Diseases, Inborn/blood , Genetic Diseases, Inborn/complications , Humans , Leukocyte Count , Leukopenia/blood , Leukopenia/complications , Male , Middle Aged , Mycobacterium , Mycobacterium Infections/blood , Mycobacterium Infections/etiology , Mycoses/blood , Mycoses/etiology , Myelodysplastic Syndromes/blood , Myelodysplastic Syndromes/etiology , Neoplasms/blood , Neoplasms/etiology , Neoplasms/genetics , Papillomaviridae , Papillomavirus Infections/blood , Papillomavirus Infections/etiology
12.
J Am Acad Dermatol ; 62(1): 31-37, 2010 Jan.
Article in English | MEDLINE | ID: mdl-19896749

ABSTRACT

BACKGROUND: Voriconazole is a broad-spectrum antifungal agent associated with photosensitivity and accelerated photoaging. A possible link with aggressive squamous cell carcinoma (SCC) has also been reported. OBJECTIVE: We sought to determine the incidence and frequency of cutaneous SCC among patients undergoing long-term treatment with voriconazole who also manifest features of chronic phototoxicity. METHODS: We conducted a retrospective review of patients who developed one or more squamous cell neoplasms during long-term treatment with voriconazole at 3 academic dermatology centers. RESULTS: A total of 51 cutaneous SCC were identified in 8 patients (median age 34.5 years, range 9-54) treated with chronic voriconazole (median duration 46.5 months, range 13-60). Underlying diagnoses included graft-versus-host disease, HIV, and Wegener granulomatosis. Signs of chronic phototoxicity and accelerated photoaging included erythema, actinic keratoses, and lentigo formation. LIMITATIONS: The retrospective nature of the study cannot determine the true population risk of SCC associated with voriconazole therapy. A prospective cohort study is needed. CONCLUSION: A high index of suspicion for photosensitivity and SCC may be warranted with chronic voriconazole use when used in the setting of concurrent immunosuppression.


Subject(s)
Antifungal Agents/adverse effects , Carcinoma, Squamous Cell/chemically induced , Dermatitis, Phototoxic/etiology , Pyrimidines/adverse effects , Skin Neoplasms/chemically induced , Triazoles/adverse effects , Adolescent , Adult , Antifungal Agents/administration & dosage , Carcinoma, Squamous Cell/epidemiology , Carcinoma, Squamous Cell/secondary , Child , Comorbidity , DNA Damage/radiation effects , Dermatitis, Phototoxic/epidemiology , Dermatitis, Phototoxic/genetics , Fatal Outcome , Female , Hematopoietic Stem Cell Transplantation , Humans , Immunocompromised Host , Middle Aged , Pyrimidines/administration & dosage , Retrospective Studies , Skin Neoplasms/epidemiology , Skin Neoplasms/pathology , Triazoles/administration & dosage , Voriconazole , Young Adult
13.
N Engl J Med ; 361(21): 2046-55, 2009 Nov 19.
Article in English | MEDLINE | ID: mdl-19776401

ABSTRACT

BACKGROUND: Recurrent sinopulmonary and cutaneous viral infections with elevated serum levels of IgE are features of some variants of combined immunodeficiency. The genetic causes of these variants are unknown. METHODS: We collected longitudinal clinical data on 11 patients from eight families who had recurrent sinopulmonary and cutaneous viral infections. We performed comparative genomic hybridization arrays and targeted gene sequencing. Variants with predicted loss-of-expression mutations were confirmed by means of a quantitative reverse-transcriptase-polymerase-chain-reaction assay and immunoblotting. We evaluated the number and function of lymphocytes with the use of in vitro assays and flow cytometry. RESULTS: Patients had recurrent otitis media, sinusitis, and pneumonias; recurrent Staphylococcus aureus skin infections with otitis externa; recurrent, severe herpes simplex virus or herpes zoster infections; extensive and persistent infections with molluscum contagiosum; and human papillomavirus infections. Most patients had severe atopy with anaphylaxis; several had squamous-cell carcinomas, and one had T-cell lymphoma-leukemia. Elevated serum IgE levels, hypereosinophilia, low numbers of T cells and B cells, low serum IgM levels, and variable IgG antibody responses were common. Expansion in vitro of activated CD8 T cells was impaired. Novel homozygous or compound heterozygous deletions and point mutations in the gene encoding the dedicator of cytokinesis 8 protein (DOCK8) led to the absence of DOCK8 protein in lymphocytes. CONCLUSIONS: Autosomal recessive DOCK8 deficiency is associated with a novel variant of combined immunodeficiency.


Subject(s)
Gene Deletion , Guanine Nucleotide Exchange Factors/genetics , Severe Combined Immunodeficiency/genetics , CD8-Positive T-Lymphocytes/physiology , Female , Genes, Recessive , Guanine Nucleotide Exchange Factors/metabolism , Humans , Immunoglobulins/blood , Longitudinal Studies , Lymphocyte Activation , Male , Pedigree , Respiratory Tract Infections/genetics , Respiratory Tract Infections/immunology , Severe Combined Immunodeficiency/immunology , Skin Diseases, Infectious/genetics , Skin Diseases, Infectious/immunology
14.
Arch Dermatol ; 145(8): 918-22, 2009 Aug.
Article in English | MEDLINE | ID: mdl-19687424

ABSTRACT

BACKGROUND: Sclerotic-type chronic graft-vs-host disease (cGVHD) of the skin is an uncommon but potentially debilitating sequela of allogeneic hematopoietic stem cell transplantation. There is no standardized assessment measure for this form of cGVHD. Because a full-thickness incisional biopsy specimen to the level of the fascia may be needed to make a definitive histologic diagnosis of cGVHD-related fasciitis, a noninvasive technique for the assessment and monitoring of sclerotic-type cGVHD, particularly cGVHD-related fasciitis, would be of potential value. OBSERVATIONS: Sixty-two consecutive patients with cGVHD following allogeneic hematopoietic stem cell transplantation were evaluated for sclerotic skin disease. Forty-four patients (71%) had cutaneous cGVHD, and 28 patients (45%) had evidence of sclerotic involvement based on physical examination findings. Fifteen patients agreed to undergo research magnetic resonance imaging to evaluate quantifiable changes in the dermis, subcutaneous tissue, and muscle. Among 15 patients, magnetic resonance imaging identified abnormalities in the skin in 7 (47%), subcutaneous fibrous septa in 13 (87%), deep fascia in 12 (80%), epimysium in 9 (60%), and muscle in 3 (20%). CONCLUSIONS: Magnetic resonance imaging should be considered in the evaluation of patients with cGVHD suspected of having subcutaneous or fascial involvement. Additional studies are needed to validate this noninvasive modality for serial monitoring of disease activity and response to therapy. Trial Registration clinicaltrials.gov Identifier: NCT00331968.


Subject(s)
Graft vs Host Disease/diagnosis , Hematopoietic Stem Cell Transplantation/adverse effects , Magnetic Resonance Imaging , Skin Diseases/diagnosis , Skin/pathology , Adult , Contrast Media , Fasciitis/diagnosis , Fasciitis/etiology , Female , Gadolinium DTPA , Graft vs Host Disease/etiology , Humans , Male , Middle Aged , Sclerosis , Skin Diseases/etiology , Young Adult
15.
Arch Dermatol ; 145(8): 923-5, 2009 Aug.
Article in English | MEDLINE | ID: mdl-19687425

ABSTRACT

BACKGROUND: Photosensitivity has been reported in patients who were treated with vandetanib (ZD6474), an inhibitor of epidermal growth factor receptor, vascular endothelial growth factor receptor, and the RET (rearranged during transfection) kinases. OBSERVATIONS: We describe the occurrence of cutaneous hyperpigmentation after photosensitivity in 2 patients who were treated with vandetanib. The pigmentation patterns were variable within and between patients. Biopsy specimens from different sites revealed variability in Perls and Fontana staining patterns. CONCLUSIONS: These 2 cases highlight the unusual occurrence of cutaneous hyperpigmentation after vandetanib-associated photosensitivity, a reaction that demonstrates that medications are important causes of acquired photosensitivity and hyperpigmentation. Aggressive photoprotection may facilitate the resolution of diffuse hyperpigmentation. Dermatologists should endeavor to identify and report novel cutaneous adverse effects as new targeted therapies are developed.


Subject(s)
Antineoplastic Agents/adverse effects , Dermatitis, Phototoxic/etiology , Piperidines/adverse effects , Quinazolines/adverse effects , Aged , Antineoplastic Agents/therapeutic use , Dermatitis, Phototoxic/pathology , Female , Humans , Hyperpigmentation/chemically induced , Hyperpigmentation/pathology , Middle Aged , Piperidines/therapeutic use , Protein-Tyrosine Kinases/antagonists & inhibitors , Quinazolines/therapeutic use , Receptors, Vascular Endothelial Growth Factor/antagonists & inhibitors , Skin/pathology
18.
BMC Dermatol ; 9: 8, 2009 Jul 28.
Article in English | MEDLINE | ID: mdl-19638218

ABSTRACT

BACKGROUND: Familial keloids have been reported, having either autosomal dominant or autosomal recessive inheritance. We wished to determine the inheritance pattern and phenotype of keloids among multigenerational families, as a prelude to a positional mapping strategy to identify candidate genes. METHODS: We studied three African American families, one Afro-Caribbean family and one Asian-American family. Phenotyping including assessing all patients for the presence, distribution, and appearance of keloids, together with the timing of keloid onset and provocative factors. The clinical trial was registered at clinicaltrials.gov (NCT 00005802). RESULTS: Age of keloid onset varied considerably within families, but commonly occurred by the second decade. The fraction of affected individuals was 38%, 45%, 62%, 67% and 73% among the five families respectively. Keloid severity and morphology differed within and between families. A novel finding is that certain families manifest keloids in distinct locations, with one family showing an excess of extremity keloids and two families showing an excess of axilla-groin keloids. CONCLUSION: Familial keloids appear to most commonly manifest autosomal dominant or semidominant inheritance, and there may be familial patterns of keloid distribution.


Subject(s)
Keloid/genetics , Adult , Black or African American , Age of Onset , Caribbean Region/ethnology , Female , Humans , Keloid/diagnosis , Keloid/epidemiology , Keloid/ethnology , Male , Pedigree , United States
19.
N Engl J Med ; 360(23): 2426-37, 2009 Jun 04.
Article in English | MEDLINE | ID: mdl-19494218

ABSTRACT

BACKGROUND: Autoinflammatory diseases manifest inflammation without evidence of infection, high-titer autoantibodies, or autoreactive T cells. We report a disorder caused by mutations of IL1RN, which encodes the interleukin-1-receptor antagonist, with prominent involvement of skin and bone. METHODS: We studied nine children from six families who had neonatal onset of sterile multifocal osteomyelitis, periostitis, and pustulosis. Response to empirical treatment with the recombinant interleukin-1-receptor antagonist anakinra in the first patient prompted us to test for the presence of mutations and changes in proteins and their function in interleukin-1-pathway genes including IL1RN. RESULTS: We identified homozygous mutations of IL1RN in nine affected children, from one family from Newfoundland, Canada, three families from The Netherlands, and one consanguineous family from Lebanon. A nonconsanguineous patient from Puerto Rico was homozygous for a genomic deletion that includes IL1RN and five other interleukin-1-family members. At least three of the mutations are founder mutations; heterozygous carriers were asymptomatic, with no cytokine abnormalities in vitro. The IL1RN mutations resulted in a truncated protein that is not secreted, thereby rendering cells hyperresponsive to interleukin-1beta stimulation. Patients treated with anakinra responded rapidly. CONCLUSIONS: We propose the term deficiency of the interleukin-1-receptor antagonist, or DIRA, to denote this autosomal recessive autoinflammatory disease caused by mutations affecting IL1RN. The absence of interleukin-1-receptor antagonist allows unopposed action of interleukin-1, resulting in life-threatening systemic inflammation with skin and bone involvement. (ClinicalTrials.gov number, NCT00059748.)


Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Autoimmune Diseases/genetics , Inflammation/immunology , Interleukin 1 Receptor Antagonist Protein/therapeutic use , Receptors, Interleukin-1/antagonists & inhibitors , Autoimmune Diseases/drug therapy , Base Sequence , Child , Female , Genes, Recessive , Homozygote , Humans , Infant , Infant, Newborn , Inflammation/drug therapy , Inflammation/genetics , Interleukin 1 Receptor Antagonist Protein/deficiency , Interleukin 1 Receptor Antagonist Protein/genetics , Interleukin-1/genetics , Interleukin-1/physiology , Interleukin-1beta/antagonists & inhibitors , Male , Mutation , Pedigree , RNA, Messenger/metabolism
20.
Science ; 324(5931): 1190-2, 2009 May 29.
Article in English | MEDLINE | ID: mdl-19478181

ABSTRACT

Human skin is a large, heterogeneous organ that protects the body from pathogens while sustaining microorganisms that influence human health and disease. Our analysis of 16S ribosomal RNA gene sequences obtained from 20 distinct skin sites of healthy humans revealed that physiologically comparable sites harbor similar bacterial communities. The complexity and stability of the microbial community are dependent on the specific characteristics of the skin site. This topographical and temporal survey provides a baseline for studies that examine the role of bacterial communities in disease states and the microbial interdependencies required to maintain healthy skin.


Subject(s)
Bacteria/isolation & purification , Metagenome , Skin/microbiology , Actinobacteria/classification , Actinobacteria/genetics , Actinobacteria/isolation & purification , Adult , Bacteria/classification , Bacteria/genetics , Bacteroidetes/classification , Bacteroidetes/genetics , Bacteroidetes/isolation & purification , Biodiversity , Female , Genes, rRNA , Humans , Male , Molecular Sequence Data , Phylogeny , Proteobacteria/classification , Proteobacteria/genetics , Proteobacteria/isolation & purification , RNA, Ribosomal, 16S , Time Factors , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL
...